Success Stories

Highlights of the PCI news focused on Penn commercialization accomplishments

Exyn Technologies Secures $35M in Series B Funding

Penn spinout Exyn Technologies, a pioneer in multi-platform robotic autonomy for complex, GPS-denied environments, had a $35 million Series B round at the end of 2022.

Penn Spinout Avisi Technologies Raises $4.06 Million in Seed Round To Be Used to Develop Glaucoma Treatment Device

Avisi was founded in 2017 by Penn students Rui Jing J., the company's CEO, and Brandon Kao and Adarsh Battu, who were studying business and engineering.

Avisi Technologies Closes $4 Million Seed Round to Further Develop Glaucoma Treatment Device

Penn spinout Avisi Technologies raised $4.06 million in a seed round led by Accanto Partners.

Neuralert Technologies included in TIME’s List of the Best Inventions 

The lightweight, non-invasive wristband device can detect the stroke symptoms in as little as 15 minutes.

Penn ranks #5 for undergraduate founders and #6 for graduate founders in Pitchbook Data’s ‘Top 100 colleges ranked by startup founders’

Penn ranked #5 for undergraduate founders and #6 for graduate founders. It also ranked #4 for female undergraduate founders and #5 for female graduate founders.

The Power of Pennovation Works: Research and Development

In November, in recognition of the 5th year anniversary of Pennovation Works, the Pennovation Center hosted The Power of Pennovation Works: Research and Development panel.

Team of Leading Scientists unite to launch Capstan Therapeutics

Penn spinout Capstan Therapeutics unites decades of combined experience in groundbreaking CAR therapies with the latest advances in mRNA delivery technology to find new cures for cancer and other dise

Innervace Secures Up to $40 Million to Advance Novel Regenerative Medicine Platform for Neurological Disorders

Innervace, a regenerative medicine startup cofounded by Penn Medicine’s Kacy Cullen, PhD, and Douglas Smith, PhD raised up to $40 million in Series A financing. 

iECURE Gets Early FDA Designation

The company was awarded FDA orphan drug designation for its experimental therapy, GTP-506, on the heels of the drug receiving rare pediatric disease designation.

Penn Engineering Commercialization Speaker Series

This fall, the Penn Center for Innovation and Penn Engineering present three monthly sessions with expert speakers, who will discuss funding, pitching, and open source software for commercialization.


Skip to content